<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900913</url>
  </required_header>
  <id_info>
    <org_study_id>StV 24-2008</org_study_id>
    <nct_id>NCT00900913</nct_id>
  </id_info>
  <brief_title>Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral Nerve Excitability</brief_title>
  <official_title>Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of intravenous ropivacaine and lidocaine
      on the receptive field of primary sensory afferents and their influence on the vascular bed.

      *Trial with medicinal product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aera of flare reaction (cm2), area of primary and secondary hyperalgesia (cm2)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine (Naropin)</intervention_name>
    <description>intravenous infusion 1 mg/kg bw</description>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male

          2. Age: 18 - 65 years

          3. Weight: 50-100kg

          4. Height: 155-195cm

          5. Signed and dated informed consent

          6. Sufficient command of German language

        Exclusion criteria:

          1. Contraindications to the class of drugs under study

          2. Vulnerable subjects (intellectually or mental impaired)

          3. Known hypersensitivity to class of drugs or the investigational product

          4. Drug abuse

          5. Known peripheral neuropathies

          6. Diabetes mellitus

          7. Chronic alcohol consumption

          8. Congestive heart disease

          9. Participants of other studies during study period

         10. Smoker
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Konrad Maurer</name_title>
    <organization>Institute of Anesthesiology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

